Press Releases

We are extremely pleased to announce that the US Patent and Trademark Office has granted to InMode Patent No. 10.799.285 covering its Morphues8 full body fractional radiofrequency (RF) technology.

INMODE INTRODUCES MORPHEUS 8 BODY WITH MULTI-PULSE BURST TECHNOLOGY. Sydney, Australia, October 23rd, 2020 - InMode Ltd (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to introduce to the market the Morpheus8 Body Multi-pulse Burst Radiofrequency Vulcanization Technology.   Expanding on the recent launch of the Morpheus8 Body Subdermal Adipose Remodelling Device (SARD), the first and only FDA cleared and TGA listed technology to penetrate tissue with a thermal profile of 8mm, comes Morpheus8 Body multi pulse Burst Technology.  This groundbreaking, industry-first, fractional technology automatically deploys bipolar RF energy to multi-level treatment depths in a single cycle.  The ability to target tissue sequentially at three levels, in millisecond intervals, allows for a significant reduction in treatment times, minimises skin injury, increases treatment uniformity, and enables customised full body fractional procedures beyond anything previously available.  "Morpheus8 Burst RF technology was predicated on the principles of the Vulcanization Process for cross linking rubber molecules to improve elasticity and tensile strength," said Dr. Spero Theodorou, InMode Chief Medical Officer. "Burst mode mediated RF Vulcanization involves a 3-step process, forming cross links between long collagen fiber molecules in a stratified depth range, to brace the Fibro Septal Network (FSN) and ultimately strengthen the overall skin-adipose scaffold. We are very proud to bring this unprecedented, highly efficacious modality to RF fractional treatments." InMode President of North America, Shakil Lakhani, commented, "With the recent launch of Morpheus8 Body, InMode pioneered full body fractional treatments. The subsequent commercialization of Morpheus8 Burst with multi-level energy deployment unequivocally solidifies InMode as the fractional market leader. Our robust innovation pipeline continues to redefine the medical aesthetics industry and further differentiates InMode as the frontrunner for delivering leading-edge treatment solutions." About InMode  InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted, minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynaecology, dermatology, otolaryngology and ophthalmology.   For more information about InMode, please visit INMODE

Sydney, Australia, September 17th, 2020 - InMode Ltd (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to announce the expansion of the unique Morpheus8 RF Microneedling technology by introducing Morpheus8 Body. Morpheus8 Body is the first intelligent, programmable, full body fractional technology to deliver clinically proven radiofrequency (RF) energy up to a thermal depth of 8mm (7mm pin depth plus an additional 1mm heat thermal profile) with its 40 gold coated pins.  As the first and only FDA cleared and TGA listed  technology to penetrate subdermal tissue with a thermal profile of 8mm, the new Morpheus8 Body technology is designed to provide physicians with a faster, bigger and better solution to deliver customisable full body fractional treatments. Based on the success of InMode's proprietary technology, the new Morpheus8 extends its line of Subdermal Adipose Remodelling Devices (SARD). The new Morpheus8 platform is the complete state-of-the-art workstation with dual handpieces and four fractional tips with different microneedle configurations: Prime 12 pin, Resurfacing 24 pin, Morpheus8 24 pin and Body 40 pin. The Morpheus8 platform provides clinics with a standalone solution for fractional RF, ranging from the Morpheus8 Prime for the treatment of delicate areas with high tissue curvature such as the eyes and nasolabial fold, to the Morpheus8 Body for large zones such as the abdomen, thighs and buttocks. Dennis Cronje, Managing Director of InMode Australia, commented "The addition of Morpheus8 Prime and Body provides a complete fractional RF solution unlike anything available currently. These new treatment modalities can provide a customisable, full body solution for each patient. True innovation in the industry has become scarce and this is where InMode will continue to thrive. We are excited about the new treatment capabilities for both our physicians and their patients". Dr. Stephen Mulholland added, "Morpheus8 has become a standard treatment in my clinic. Whether I use it as a stand-alone treatment for tightening and smoothing of the skin or combined with one of my other treatments, it is my go-to treatment for patients looking for significant, but non-surgical, remodelling improvement”.   About InMode  InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted, minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynaecology, dermatology, otolaryngology and ophthalmology.    For more information about InMode, please visit www.inmode.com.au